Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan

Pediatrics International

Volumn 53, Issue 3, 2011, Pages 368-373

  Kusuda, Satoshi ^a,b   Takahashi, Naoto ^b   Saitoh, Takami ^b   Terai, Masaru ^b   Kaneda, Hisashi ^b   Kato, Yuichi ^b   Ohashi, Atsushi ^b   Watabe, Shinichi ^b   Joh O, Kunitaka ^b   Hirai, Katsuki ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b RSV Hospitalization Survey Group   (Japan)

Author keywords

hospitalizations; palivizumab; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT; JAPAN; MAJOR CLINICAL STUDY; NEWBORN; PEDIATRIC WARD; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; WINTER;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; JAPAN; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79959748044     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03249.x     Document Type: Article

References (16)

1. Marshall E,. Visiting experts find the "mystery disease" of Naples is a common virus. Science 1979; 9: 980-1.
2. McIntosh K,. Respiratory syncytial virus. In:, Evans AS, Kaslow RA, (eds). Viral Infections of Humans. Plenum Publishing, New York, 1997; 691-711.
3. Navas L, Wang E, de Carvalho V, Robinson J,. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J. Pediatr. 1992; 121: 348-54.
4. Subramanian KN, Weisman LE, Rhodes T, et al,. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr. Infect. Dis. J. 1999; 18: 223-231.
5. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211-16.
6. Meissner HC, Welliver RC, Chartrand SA, et al,. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion. Pediatr. Infect. Dis. J. 1999; 18: 223-31. (Pubitemid 29128367)
7. Groothuis JR, Nishida H,. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr. Int. 2002; 44: 235-4.
8. Kusuda S, Koizumi T, Sakai T, Fujimura M, Nishida H, Togari H,. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr. Int. 2006; 48: 362-8. (Pubitemid 44127885)
9. Nakazawa M, Saji T, Ichida F, Oyama K, Harada K, Kusuda S,. Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr. Int. 2006; 48: 190-3.
10. Infectious disease surveillance center. Isolation and detection of viruses. [Cited 5 September 2008.] Available from URL
11. Mother's & Children's Health & Welfare Association. Maternal and child health statistics of Japan. 2009.
12. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
13. Saijo M, Ishii T, Kokubo M, Takimoto M, Takahashi Y,. Respiratory syncytial virus infection in lower respiratory tract and asthma attack in hospitalized children in North Hokkaido, Japan. Acta Paediatr. Jpn. 1993; 35: 233-7. (Pubitemid 23162556)
14. Kaneko M, Watanabe J, Ueno E, Hida M, Sone T,. Risk factors for severe respiratory syncytial virus-associated lower respiratory tract infection in children. Pediatr. Int. 2001; 43: 489-92. (Pubitemid 34205845)
15. Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M,. Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 891-9.
16. Paes B, Cole M, Latchman A, Pinelli J,. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Curr. Med. Res. Opin. 2009; 25: 2191-6.